NEW YORK and HERZLIYA, Israel, Feb. 12, 2025 /PRNewswire/ -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), announces today that Mr. Ehud Barak will step down as Chairman of the board of directors of the Company (the "Board"), effective February 13, 2025. He will be succeeded by Mr. Alexander Rabinovich, who has successfully led the Company as CEO for the past five years, executing hundreds of percentages of profitable growth, building strategic international partnerships, and establishing InterCure's position as a leader in pharmaceutical cannabis. Mr. Barak, who is marking his 83rd birthday today, has decided to pursue personal endeavors after six

The funding may increase to NIS 107M to support the expansion of the facility in collaboration with the "Tkumah" administration, post-war.The funding includes investments from key shareholders of the company, including CEO Alexander Rabinovich, as well as lead investors Yaron Yakobi and Tzahi Hagag who will become significant shareholders. Funding also includes a loan from a major Israeli bank.Completing the post-war damage recovery processes will enable the company to return to profitable growth without further delay, including exercising the cookies agreement and expanding international operations in Germany, the UK, and Australia.The Company anticipates receiving additional substantial p

Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA1of NIS 21 million (Approximately 17% of revenues).Both quarters (Q1 and Q2 of 2024) ended with positive EBITDAs and profit from operations and represents InterCure's 16th and 17th consecutive quarter of profitability2.Revenues for the first half of 2024 were affected by damages caused by the terrorist attack on October 7, 2023, and the war in Gaza. InterCure is entitled to full compensation from the Israeli authorities for all direct and indirect damages caused to its Southern Facility located at Kibbutz Nir Oz. To date, InterCure has already received tens of millions of NIS as partial advance paymen

InterCure expands its European footprint to launch Cookies Corners licensed pharmacies in Germany alongside differentiated online platforms with the official cookies retail experience, enhancing branded product offerings with the most-recognized global cannabis brand. InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading vertically integrated medical cannabis company outside of North America, is announcing a new strategic agreement with Cookies, the globally recognized cannabis brand, to cultivate, manufacture, import and distribute Cookies' branded products, produced from its cultivation and manufacturing facilities, initially in 8 licensed b

InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference. The conference is scheduled for tomorrow, May 23, 2024, at the Westin NY Grand Central Hotel in New York City. This prestigious event will bring together senior management teams from leading cannabis companies including InterCure CEO Alex Rabinovitch, to engage in panel discussions, fireside chats, and one-on-one meetings. For more information about the event please refer to the following link: https://www.canaccordgenuity.com/capital-markets/events-and-conferences/

Revenues during 2023 reached NIS 356 million, alongside an Adjusted EBITDA1 of NIS 61 million (Approximately 17% of revenues), as compared to an Adjusted EBITDA of NIS 51 million in our preliminary results. The Company's cash2 on hand was NIS 111 million. Both Q3&Q4 ended with positive EBITDAs and profit from operations3 and represents InterCure's fourteenth & fifteenth consecutive quarter of profitability4. Revenues for H2 2023 were affected by damages caused by the terrorist attack on October 7, 2023 and the war in Gaza. InterCure is entitled to full compensation from the Israeli authorities for all direct and indirect damages caused to the Southern Facility. To date, InterCure

Revenues for H2 2023 were affected by damages caused by the terrorist attack on October 7, 2023 and the war in Gaza. However, InterCure it is entitled to full compensation from the Israeli authorities for all direct and indirect damages caused. To date, InterCure has already received tens of millions of shekels as partial advanced payments from the Israeli authorities. H2 2023's estimated EBITDA1 to reach over NIS 20 million and over 14% of revenues. Both Q3&Q4 ended with positive EBITDAs and profit from operations and represents InterCure's fourteenth & fifteenth consecutive quarter of profitability2. Expects to launch its first products in Germany in the coming months and contin

InterCure provides an update following recent Cannabis Reform in Germany Expects to launch its first products in Germany in the coming months The Company continues to closely watch developments surrounding Cannabis rescheduling in the U.S. InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside of North America, is thrilled to congratulate The Federal Republic of Germany for the passing of the "CannG" Cannabis Act, which is expected to take effect on April 1, 2024. On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months. While the

NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company's press release issued on October 17, 2023, in which the Company provided an update regarding the status of the security situation in Israel, and its impact on the Company and its employees, the Company is providing an additional update regarding the status of its facility in Kibbutz Nir Oz (the "Southern Israel Site"). Since October 7, 2023, war situation was declared by the Israeli government. As of this date, there

NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, announced today that it has entered into a share purchase agreement (the "Agreement") with the shareholders of Leon Pharm Ltd. (the "Sellers", and "Leon Pharm", respectively) to purchase Leon Pharm, a leading, Israel-based pharmacy chain specializing in dispensing medical cannabis in Israel, by way of a share purchase of all of the issued and outstanding share capital of Leon Pharm (the "Transaction").   At the closing, InterCure will cause between 1,755,000 to

Canaccord Genuity upgraded InterCure from Speculative Buy to Buy and set a new price target of $13.00

6-K - Intercure Ltd. (0001857030) (Filer)

6-K/A - Intercure Ltd. (0001857030) (Filer)

6-K - Intercure Ltd. (0001857030) (Filer)

6-K - Intercure Ltd. (0001857030) (Filer)

6-K - Intercure Ltd. (0001857030) (Filer)

6-K - Intercure Ltd. (0001857030) (Filer)

6-K - Intercure Ltd. (0001857030) (Filer)

6-K - Intercure Ltd. (0001857030) (Filer)

6-K - Intercure Ltd. (0001857030) (Filer)

6-K/A - Intercure Ltd. (0001857030) (Filer)

NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022. The call was originally scheduled for April 3 at 4:30 P.M. (Eastren time) but has been rescheduled to April 4, at 4:30 P.M. (Eastren time) due to unforeseen circumstances which caused technical issues. Participants can access the live webcast and conference call through the following link: https://register.vevent.com/register/BIdec7603751894ebcbf0f22eca9

Record fiscal year 2022 revenue of $150 million Record fiscal year 2022 Adjusted EBITDA* of $32 million Record fiscal year 2022 net income of $17 million Generated $20 Million cash flow from operations Strong balance sheet with over $95 million cash NEW YORK, TORONTO, and HERZLIYA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2022. All amounts are expressed in New Israeli Shekels (NIS) or Canadian dollars ($), unless otherwise noted. Full Year 2022 Key Financial & Operating High

Record revenue of over $37 millioni in the second quarter of 2022 Representing an annual run rate of $150 million Adjusted EBITDAii for Q2 increased 90% YoY to $9 million Net income of $6 million for the Q2 of 2022 compared to $2 million in Q2 of 2021 Tenth consecutive quarter of profitable growth Eighth consecutive quarter of positive cash flow from operations $96 million cash on hand Revenue growth expected to continue in the third quarter and throughout 2022 NEW YORK and TORONTO and HERZLIYA, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial results

NEW YORK and TORONTO and HERZLIYA, Israel, Aug. 11, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") today announced that it plans to release financial results for the second quarter of 2022 after market close on Monday, August 15, 2022. InterCure executives will host a live conference call and audio webcast to discuss these results on Tuesday, August 16, 2022, at 8:30 am Eastern Time, details of which are provided below. To access the conference call, participants can register through the following URL: https://register.vevent.com/register/BI5e6af40482ac4b7bb3024b6aad2c8185. Once registered participants will recei

Record revenue of $341 million in the first quarter of 2022 Adjusted EBITDA2 increased almost 110% year-over-year to $8 million Net income of $6 million for the Q1 of 2022 compared to $2 million in Q1 of 2021 Seventh consecutive quarter of positive cash flow from operations $91 million cash on March 31, 2022 Revenue growth expected to continue in the second quarter and throughout 2022 NEW YORK and TORONTO and HERZLIYA, Israel , May 16, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") is pleased to announced its financial results for the first quarter of 2022 and is pleased to provide sha

NEW YORK and TORONTO and HERZLIYA, Israel, May 16, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") today announced that it plans to release financial results for the first quarter of 2022 after market close on Monday, May 16, 2022. The Company will conduct a conference call on Tuesday, May 17, 2022, at 8:00a.m. (Eastern Time) to review the results as well as provide an overview of the Company's recent milestones and growth strategy. InterCure executives will host a live conference call and audio webcast to discuss these results on Tuesday, May 17, 2022, at 8:00 am Eastern Time, details of which are provided below.

Another record year with continued industry leading growth and profitability supported by focused strategy and execution Revenue growth expected to continue in the first quarter and throughout 2022 Strong balance sheet with $89 million cash supporting future profitable growth NEW YORK and TORONTO and HERZLIYA, Israel, April 05, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2021. References herein to "preliminary results" refer to the preliminary results published by the Company on February 8, 2022. All

Fourth quarter 2021 Revenue and Adjusted EBITDA2 of $33 million and $9 million, representing an increase of almost 200% and 140% YoY, respectively Record fiscal year 2021 revenue and Adjusted EBITDA2 of $89 million and $23 million, representing an increase of over 230% and of almost 250% YoY, respectively Estimated net income of $5 million for 2021 Strong balance sheet with $89 million cash Six consecutive quarters with positive cash flow from operations Revenue growth expected to continue in the first quarter and throughout 2022 NEW YORK, TORONTO, and HERZLIYA, Israel, April 04, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure

Will release financial results for the fourth quarter of 2021 before market open on Monday, April 4, 2022 Webcast scheduled for same day at 8:30am ET NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") today announced that the Company will release financial results for its fourth quarter fiscal 2021 ended December 31, 2021 before financial markets open on April 4, 2022. InterCure executives will host a live conference call and audio webcast to discuss these results at 8:30 am Eastern Time, details of which are provided below. To access the conference call, United St

NEW YORK, TORONTO, and HERZLIYA, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") today announced that it plans to release financial results for the fourth quarter of 2021 after market close on Thursday, March 31, 2022. The Company will conduct a webcast on Monday, April 4, 2022 at 8:30 a.m. (Eastern Time) to review the results as well as provide an overview of the Company's recent milestones and growth strategy. To access the conference call, United States participants please dial (844) 310-5056, or for international callers, 1-706-679-4749. Conference ID: 5661207. Participants can access the liv

SC 13G - Intercure Ltd. (0001857030) (Subject)